Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $17.00 at HC Wainwright

Cardiff Oncology (NASDAQ:CRDF) had its target price hoisted by HC Wainwright from $13.00 to $17.00 in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Piper Sandler increased their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, December 13th.

Cardiff Oncology Trading Up 4.4 %

Shares of NASDAQ:CRDF opened at $4.24 on Friday. Cardiff Oncology has a 12-month low of $2.00 and a 12-month high of $6.42. The business has a 50 day moving average of $4.06 and a two-hundred day moving average of $3.23. The company has a market capitalization of $216.81 million, a PE ratio of -4.51 and a beta of 1.77.

Insiders Place Their Bets

In other news, Director Gary W. Pace purchased 350,115 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average price of $2.60 per share, with a total value of $910,299.00. Following the purchase, the director now directly owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This represents a 50.18 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 7.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new stake in Cardiff Oncology in the fourth quarter valued at $25,000. ProShare Advisors LLC acquired a new stake in shares of Cardiff Oncology during the 4th quarter worth about $50,000. Raymond James Financial Inc. acquired a new stake in shares of Cardiff Oncology during the 4th quarter worth about $56,000. Voya Investment Management LLC purchased a new stake in Cardiff Oncology in the 4th quarter valued at about $57,000. Finally, Caxton Corp acquired a new position in Cardiff Oncology in the fourth quarter valued at about $58,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.